{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"description":"Complete response requires both a pathological complete response (independent of observer) and a complete response radiologically (RECIST 1.0).","groups":[{"description":"Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47.","id":"OG000","title":"Arm A (Cisplatin and Radiotherapy)"},{"description":"Patients receive cisplatin and radiotherapy as in Arm A. Patients also receive erlotinib hydrochloride PO daily on days -7 to 47.","id":"OG001","title":"Arm B (Cisplatin, Radiotherapy, Erlotinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 weeks after the completion of therapy","title":"Comparison of the Percentage of Participants With a Complete Response in Each Treatment Arm","type":"PRIMARY","unitOfMeasure":"percentage of participants"}